A series of 211 patients with systemic lupus erythematosus (SLE) was presented, 84 of whom had initial renal involvement; 81 of 211 patients were treated with HN2; 130 of 211 patients were not treated with HN2 and tend to assume the role of a control group. Although it is difficult to draw any specific conclusions because of the wide range of variations in patients with SLE, there appears to be a definite and beneficial longterm effect from the use of HN2 in lupus erythematosus (LE) nephropathy.
KELLUM RE, HASERICK JR. Mechlorethamine Therapy for Systemic Lupus NephropathyAnalysis and Review of Ten Years' Experience and a Clinical Study of 211 Cases Including 81 Patients Treated With Mechlorethamine. Arch Dermatol. 1963;87(3):289–298. doi:10.1001/archderm.1963.01590150005001
Customize your JAMA Network experience by selecting one or more topics from the list below.